Tofranil 25 mg
Hypersensitivity to imipramine. Acute recovery period after MI use within 14 days of MAOIs; initiation of imipramine in pts with concurrent use with linezolid or IV methylene blue.
Treatment of depression. Treatment of nocturnal enuresis in children older than 6
yrs. OFF-LABEL: Treatment of attention-deficit/hyperactivity disorder
(ADHD) post-traumatic stress disorder (PTSD) neurogenic pain panic disorder.
Frequent: Drowsiness fatigue dry mouth blurred vision constipation delayed
micturition orthostatic hypotension diaphoresis impaired concentration
increased appetite urinary retention photosensitivity. Occasional: GI
disturbances (nausea metallic taste). Rare: Paradoxical reactions (agitation
restlessness nightmares insomnia) extrapyramidal symptoms (EPS)
(particularly fine hand tremor).
Adverse effects/toxic reactions
Overdose may produce seizures cardiovascular effects (severe orthostatic
hypotension dizziness tachycardia palpitations arrhythmias). May result in
altered temperature regulation (hyperpyrexia hypothermia). Abrupt withdrawal
from prolonged therapy may produce headache malaise nausea vomiting vivid
hypertrophy; history of urinary retention history of bowel obstruction;
glaucoma diabetes history of seizures hyperthyroidism; cardiac hepatic renal
disease; increased intraocular pressure pts with high risk for suicide. Decreased
GI motility paralytic ileus visual problems respiratory disease elderly.